Skip to main content

Autoinflammatory

      RT @synovialjoints: Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions

      Dr. Antoni Chan synovialjoints

      3 years 11 months ago
      Treatment for VEXAS syndrome. It is steroid responsive. Avoid IL-1 inhibitors severe skin reactions at injection site, bone marrow transplant may be curative @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/eQ1KVDiKKV
      Opening Day Report
      The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford). The Year in Review featured a clinical vs basic science Brigham and Women’s Hospital faceoff between its two faculty, Dr. Karen Costenbader and Dr. Michael Brenner.
      RT @synovialjoints: VEXAS a new genetic disorder, (V) Vacuoles, (E) E1-enzyme, (X) X-linked, (A) Autoinflammatory, (S) S

      Dr. Antoni Chan synovialjoints

      3 years 11 months ago
      VEXAS a new genetic disorder, (V) Vacuoles, (E) E1-enzyme, (X) X-linked, (A) Autoinflammatory, (S) Somatic. These are the important clinical features to be looking out for in clinic @RheumNow #ACR21 Session6S410 L Wilson, DO Cordona https://t.co/dBBLox6vVg
      IL-18 in autoinflammatory Disorders session talk by Raphaela Goldbach-Mansky
      - Discovered in 1995
      - IL18 expressed in ep

      Dr. John Cush RheumNow

      3 years 11 months ago
      IL-18 in autoinflammatory Disorders session talk by Raphaela Goldbach-Mansky - Discovered in 1995 - IL18 expressed in epithelial cells, keratinocyts, macrophages - IL-18R neg regulated by IL-18 binding protein https://t.co/U6TTDqEb7L https://t.co/R2lIo188ac
      RT @bella_mehta: It is always difficult to distinguish infection and disease flares in autoinflammatory syndromes = 25 p

      Bella Mehta bella_mehta

      3 years 11 months ago
      It is always difficult to distinguish infection and disease flares in autoinflammatory syndromes = 25 pt sJIA study at #ACR21 showing serum procalcitonin levels are useful when >0.95ng/ml @StillsDis_411 @rheumnow #abst0252
      Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz dura

      Dr. John Cush RheumNow

      3 years 11 months ago

      Fautrel reports mixed response to JAK Inhib. in 8 refractory Adult (6) & juvenile (2)-Onset Still's Dz w/ dz Dz duration 86 mos (7 Systemic, 1 Chr articular) w/ JAKi (Bari 4, Upa1, Tofa 2, Ruxo 2). There were no remissions, 50% had partial response @ 11 mos #ACR21 Abstr#0195 https://t.co/Ww8ONBrRqq

      RT @Yuz6Yusof: #ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, cl

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 11 months ago

      #ACR21 #Abstr0252 Let's examine our patients than relying on tests. In sJIA pts presenting with fever, clinical features (fever pattern, rash and MSK symptoms) distinguished inflammation vs infection but not CRP, ferritin and procalcitonin @RheumNow https://t.co/s61WGBVK73 https://t.co/qhN95GdwgJ

      RT @DrPetryna: @RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can b

      Olga Petryna DrPetryna

      3 years 11 months ago
      @RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL
      RT @DrPetryna: Abst0254 #ACR21 @RheumNow CARRA SJIA cohort defines factors associated with medication free remission for

      Olga Petryna DrPetryna

      3 years 11 months ago
      Abst0254 #ACR21 @RheumNow CARRA SJIA cohort defines factors associated with medication free remission for ≥6 month-period: younger age, normal CRP levels & shorter time btw diagnosis and start of Rx. none of pts who developed MAS (3.9%) able to d/c Rx for ≥6 months
      Polyautoimmunity: axSpA and Familial Mediterranean Fever by Dr. Rachel Tate ( @uptoTate )

      Mysteries behind polyautoimm

      Dr. John Cush RheumNow

      3 years 11 months ago
      Polyautoimmunity: axSpA and Familial Mediterranean Fever by Dr. Rachel Tate ( @uptoTate ) Mysteries behind polyautoimmunity have confounded rheumatologists for decades. One such association, the co-existence of FMF and axSpA, remains rare. https://t.co/GbU1ikeyQw #ACR21 https://t.co/dRd6yxjieS
      RT @uptoTate: Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic change

      Dr. Rachel Tate uptoTate

      3 years 11 months ago

      Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

      RT @uptoTate: Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted

      Dr. Rachel Tate uptoTate

      3 years 11 months ago

      Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV

      RT @uptoTate: RELIANCE observational interim analysis in PFS pts treated w/ CAN. 168 CAPS, TRAPS, HIDS/MKD and FMF pts

      Dr. Rachel Tate uptoTate

      3 years 11 months ago

      RELIANCE observational interim analysis in PFS pts treated w/ CAN. 168 CAPS, TRAPS, HIDS/MKD and FMF pts enrolled starting 10/17 - 12/20. 101 pts experienced an AE, 9 drug-related SAE. See table below. Abs 1090 #ACR21 #RheumNow @RheumNow https://t.co/4ship1G1tY https://t.co/EFlgUGNXdD

      RT @uptoTate: RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a g

      Dr. Rachel Tate uptoTate

      3 years 11 months ago
      RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a good start, but offers questions regarding dosing of CAN in this patient population. Abs 0192 #ACR21 #RheumNow @RheumNow https://t.co/46o7AnUVj2 https://t.co/7oAPovbukl
      RT @uptoTate: RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigato

      Dr. Rachel Tate uptoTate

      3 years 11 months ago

      RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigators observed a trend toward updosing over standard dosing. Abs 0191 #ACR21 #RheumNow @RheumNow https://t.co/ik6dAEZjFf https://t.co/arqSEzuC6Q

      ×